MedPath

Evaluation of the efficacy of Sitagliptin plus peginterferon alfa 2b /ribavirin combination therapy in CHC patients with insulin resistance

Not Applicable
Conditions
Hepatitis C
Registration Number
JPRN-UMIN000003957
Lead Sponsor
Hyogo College Of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1) Pregnant , possibly pregnant or lactating women 2) Patients with severe heart diseases 3) Chronic kidney failure or creatinine clearance of <=50 mL/min 4) Current or history of severe psychiatric disorder 5) Autoimmune hepatitis 6) Intolerance to sitagliptin 7) medication for diabetes

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
SVR rate
Secondary Outcome Measures
NameTimeMethod
HOMA-IR decrease safet
© Copyright 2025. All Rights Reserved by MedPath